← Back to Screener
Capricor Therapeutics Inc (CAPR)
Price$34.59
Favorite Metrics
Price vs S&P 500 (26W)364.46%
Price vs S&P 500 (4W)7.58%
Market Capitalization$1.99B
All Metrics
Book Value / Share (Quarterly)$5.33
P/TBV (Annual)2.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)352.73%
Cash Flow / Share (Quarterly)$-1.42
Price vs S&P 500 (YTD)18.77%
Net Profit Margin (TTM)-181.71%
EPS (TTM)$-2.26
10-Day Avg Trading Volume1.07M
EPS Excl Extra (TTM)$-2.26
Revenue Growth (5Y)85.64%
EPS (Annual)$-2.26
ROI (Annual)-33.64%
Net Profit Margin (5Y Avg)-2831.28%
Cash / Share (Quarterly)$5.55
ROA (Last FY)-29.51%
Revenue Growth TTM (YoY)-52.08%
EBITD / Share (TTM)$-2.29
ROE (5Y Avg)-94.15%
Operating Margin (TTM)-191.13%
Cash Flow / Share (Annual)$-1.42
P/B Ratio6.50x
P/B Ratio (Quarterly)5.13x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)76.58x
Net Interest Coverage (TTM)7.75x
ROA (TTM)-54.59%
EV / EBITDA (TTM)3411.13x
EPS Incl Extra (Annual)$-2.26
Current Ratio (Annual)9.01x
Quick Ratio (Quarterly)8.88x
3-Month Avg Trading Volume1.52M
52-Week Price Return272.77%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.30
P/S Ratio (Annual)89.22x
Asset Turnover (Annual)0.13x
52-Week High$40.37
Operating Margin (5Y Avg)-2891.85%
EPS Excl Extra (Annual)$-2.26
CapEx CAGR (5Y)84.39%
Tangible BV CAGR (5Y)46.12%
26-Week Price Return368.45%
Quick Ratio (Annual)8.88x
13-Week Price Return42.96%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)9.01x
Enterprise Value$1,705.567
Revenue / Share Growth (5Y)18.36%
Asset Turnover (TTM)0.25x
Book Value / Share Growth (5Y)31.22%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-181.71%
Cash / Share (Annual)$5.55
3-Month Return Std Dev74.32%
Net Income / Employee (TTM)$-1
ROE (Last FY)-34.35%
Net Interest Coverage (Annual)-28.45x
EPS Basic Excl Extra (Annual)$-2.26
P/FCF (TTM)528.46x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-2.26
Receivables Turnover (Annual)0.00x
ROI (TTM)-65.77%
P/S Ratio (TTM)89.22x
Pretax Margin (5Y Avg)-2831.28%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.30
Forward P/E209.64x
Price vs S&P 500 (52W)242.94%
Year-to-Date Return21.41%
5-Day Price Return10.85%
EPS Normalized (Annual)$-2.26
ROA (5Y Avg)-39.52%
Net Profit Margin (Annual)-181.71%
Month-to-Date Return15.26%
Cash Flow / Share (TTM)$-1.11
EBITD / Share (Annual)$-2.29
Operating Margin (Annual)-191.13%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-79.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.26
P/TBV (Quarterly)2.26x
P/B Ratio (Annual)5.13x
Pretax Margin (TTM)-181.71%
Book Value / Share (Annual)$5.33
Price vs S&P 500 (13W)42.27%
Beta0.41x
P/FCF (Annual)1273.71x
Revenue / Share (TTM)$0.00
ROE (TTM)-67.52%
52-Week Low$4.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.19
4.19
4.19
4.19
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CAPRCapricor Therapeutics Inc | 89.22x | -52.08% | — | — | $34.59 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases with high unmet medical needs. Its lead candidate, deramiocel (an allogeneic cardiac-derived cell therapy), is in Phase 3 clinical development for Duchenne muscular dystrophy. The company's proprietary StealthX platform supports preclinical research in vaccine delivery and targeted molecular therapeutics.